BMS-986339

• UNSPSC Description:

  BMS-986339 is an orally active, potent FXR agonist. BMS-986339 forms H-bond with His298 and ASN287 residues. BMS-986339 can be used in the research of primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH), anti-fibrosis[1].

• Target Antigen:

  Cytochrome P450; FXR

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  Metabolism-sugar/lipid metabolism

• Field of Research:

  Metabolic Disease

• Assay Protocol:

  https://www.medchemexpress.com/bms-986339.html

• Solubility:

  10 mM in DMSO

• Smiles:

  CC(F)(C1=NC(C23CCC(CC2)(CC3)CN(C4=CC(C5=CC=C(C=C5)C(C)(O)C)=CC=C4)C([C@H]6C[C@@](O)(C6)C(F)(F)F)=O)=NO1)C

• Molecular Weight:

  643.71

• References & Citations:

  [1]Susheel J Nara, et al. Discovery of BMS-986339, a Pharmacologically Differentiated Farnesoid X Receptor Agonist for the Treatment of Nonalcoholic Steatohepatitis. J Med Chem. 2022 Jul 14;65(13):8948-8960.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2477873-64-4